Comphya, a Lausanne, Switzerland-based medical device company, raised CHF 850K in a convertible loan.
The financial round included investment from existing shareholders and additional investors. Praxis Spinal Cord Institute, a non-profit organization, also committed to participate in this financing round. This brings the total amount of funds raised to CHF 5.1M.
The company intends to use the funds to secure the start of the pilot clinical trials in Q1 2023.
Led by CEO Rodrigo Fraga-Silva, Comphya is a company developing CaverSTIM, an implantable device to restore erectile function in patients non-responsive to oral drugs. CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG), containing the rechargeable battery and electronics responsible for the generation of the electrostimulation signal; and connected to two electrodes array (with several electrodes) to be implanted in the pelvic cavity and which will activate and restore the nerves responsible for penile erection. The IPG is implanted subcutaneously in the lower abdomen and it is remotely operated by external controllers. The clinician controller allows the medical expert to adjust and tailor the system parameters to best fit each patient; and the patient controller, allows the patient to activate the device on-demand to evoke penile erection for the treatment.
The pilot clinical trials will assess the safety and preliminary efficacy of the CaverSTIM device.
FinSMEs
31/01/2023